Nichi-Iko Pledges Return To Form After Turbulent Financial Year

Japanese Firm Entered Dispute Resolution Procedure In March

Nichi-Iko experienced substantial losses over the financial year ended 31 March 2022, as one of many Japanese generics firms found to have been falling short on GMP since the beginning of 2021.

Hand placing brick into wall
Nichi-Iko is seeking to rebuild its business through the ADR process • Source: Shutterstock

Following a difficult year for the Japanese generics company, Nichi-Iko has said it aims to “revitalize and continue our business in the future and to drastically improve our financial position” after formally entering into a business turnaround alternative dispute resolution process. (Also see "Nichi-Iko Aims To Regroup As It Enters Turnaround Process" - Generics Bulletin, 25 May, 2022.)

The certified procedure allows Japanese companies to reach an agreement with its financial creditors out-of-court to avoid statutory insolvency proceedings....

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

Test

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains